09:30-09:45 Arrival and Coffee

09:45-10:45 Dr Sarantis Chlamydas (Scientific Director Multi-Omics) Precision proteomics broadens MultiOmics repertoire and enables biomarker discovery

10:45-11:00 Questions/discussion

Olink Proteomics is a Swedish company with strong global presence, that enables high-plex protein biomarker discovery and development. Olink’s platform currently has the ability to robustly measure ~3,000 analytes. It’s been used in different settings due to its scalability and actionability such as in the elucidation of pathways and mechanisms of drug action, as a screening tools for identifying signatures/biomarkers with a prognostic/predictive significance as well as to safety and toxicity studies, drug target selection and differentiation. Due to the fact that the protein library, which continuously expands, covers all major biological pathways the applications are in numerous disease areas, such as Immuno-oncology, Neurology, Cardiology, Diabetes and Rare Diseases.

In this scientific seminar we will go through a series of case studies elucidating the power of our capabilities.

As a general overview:

• We will discuss about the advantages, coverage, matrices that can be analyzed with our technology.

• How Olink technology enables biomarker identification, precision medicine and MultiOmics approaches.

• Olink technology in drug discovery and disease areas research projects.

Dr. Chlamydas is a Scientific Director specializing in MultiOmics at Olink Proteomics. He conducted his PhD in Molecular Biology and Genetics at the University of Bari and the Max Planck Institute of Immunobiology and Epigenetics. He continued his research as a research fellow in the Max Planck Institute, leading Epigenetics and Gene regulation projects applying MultiOmics approaches. During his appointments, he established a number of international collaborations with academic sites and pharma companies. Since 2020, he is a member of the University Research Institute of Athens with the honorary title of Researcher, Assistant Professor level.

Dr. Chlamydas joined Olink at the end of 2021 where he leads global efforts and strategy to advance Olink in the field of MultiOmics

QUB Genomics Month 2022 - Olink Application Seminar